AMICUS THERAPEUTICS INC's ticker is FOLD and the CUSIP is 03152W109. A total of 277 filers reported holding AMICUS THERAPEUTICS INC in Q4 2020. The put-call ratio across all filers is 0.99 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,355,098 | -10.6% | 111,439 | -7.6% | 0.00% | 0.0% |
| Q2 2023 | $1,515,565 | +15.7% | 120,666 | +2.2% | 0.00% | 0.0% |
| Q1 2023 | $1,309,685 | -6.4% | 118,096 | +3.0% | 0.00% | 0.0% |
| Q4 2022 | $1,399,461 | +30.8% | 114,616 | +11.9% | 0.00% | 0.0% |
| Q3 2022 | $1,070,000 | +15.2% | 102,445 | +18.5% | 0.00% | +50.0% |
| Q2 2022 | $929,000 | +10.3% | 86,478 | -2.7% | 0.00% | 0.0% |
| Q1 2022 | $842,000 | -18.0% | 88,891 | 0.0% | 0.00% | 0.0% |
| Q4 2021 | $1,027,000 | +21.0% | 88,891 | 0.0% | 0.00% | 0.0% |
| Q3 2021 | $849,000 | -0.9% | 88,891 | 0.0% | 0.00% | +100.0% |
| Q2 2021 | $857,000 | -2.4% | 88,891 | 0.0% | 0.00% | 0.0% |
| Q1 2021 | $878,000 | -73.9% | 88,891 | -39.0% | 0.00% | -83.3% |
| Q4 2020 | $3,364,000 | +104.4% | 145,712 | +25.0% | 0.01% | +100.0% |
| Q3 2020 | $1,646,000 | -21.3% | 116,554 | -16.0% | 0.00% | 0.0% |
| Q2 2020 | $2,091,000 | +55.9% | 138,683 | -4.4% | 0.00% | +50.0% |
| Q1 2020 | $1,341,000 | -9.3% | 145,114 | -4.4% | 0.00% | 0.0% |
| Q4 2019 | $1,478,000 | +6.3% | 151,714 | -12.5% | 0.00% | 0.0% |
| Q3 2019 | $1,390,000 | -35.9% | 173,372 | -0.1% | 0.00% | 0.0% |
| Q2 2019 | $2,167,000 | -8.2% | 173,602 | 0.0% | 0.00% | -33.3% |
| Q1 2019 | $2,361,000 | +52.1% | 173,602 | +7.2% | 0.00% | +50.0% |
| Q4 2018 | $1,552,000 | -36.4% | 162,009 | -19.8% | 0.00% | 0.0% |
| Q3 2018 | $2,442,000 | -30.6% | 201,955 | -10.4% | 0.00% | -50.0% |
| Q2 2018 | $3,521,000 | +1.5% | 225,418 | -2.3% | 0.00% | 0.0% |
| Q1 2018 | $3,470,000 | +5.0% | 230,740 | +0.5% | 0.00% | +33.3% |
| Q4 2017 | $3,305,000 | +13.0% | 229,666 | +18.4% | 0.00% | 0.0% |
| Q3 2017 | $2,924,000 | +1620.0% | 193,922 | +862.2% | 0.00% | – |
| Q1 2016 | $170,000 | -63.5% | 20,155 | -58.1% | 0.00% | -100.0% |
| Q4 2015 | $466,000 | -62.7% | 48,054 | -46.1% | 0.00% | -50.0% |
| Q3 2015 | $1,248,000 | -18.6% | 89,217 | -17.6% | 0.00% | -33.3% |
| Q2 2015 | $1,533,000 | +56.3% | 108,324 | +20.1% | 0.00% | +50.0% |
| Q1 2015 | $981,000 | +63.0% | 90,200 | +24.6% | 0.00% | +100.0% |
| Q4 2014 | $602,000 | +45.1% | 72,400 | +3.9% | 0.00% | 0.0% |
| Q3 2014 | $415,000 | – | 69,700 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Palo Alto Investors LP | 10,524,022 | $127,972,108 | 12.11% |
| Perceptive Advisors | 27,692,917 | $336,745,870 | 11.23% |
| Redmile Group, LLC | 16,944,621 | $206,046,591 | 9.80% |
| Finepoint Capital LP | 1,489,025 | $18,106,544 | 9.02% |
| CM Management, LLC | 450,000 | $5,472,000 | 5.81% |
| Avoro Capital Advisors LLC | 27,400,000 | $333,184,000 | 5.20% |
| MPM BioImpact LLC | 716,139 | $8,708,250 | 2.32% |
| Artal Group S.A. | 4,062,567 | $49,401 | 2.12% |
| SECTORAL ASSET MANAGEMENT INC | 803,464 | $9,770,122 | 1.90% |
| GREAT POINT PARTNERS LLC | 857,000 | $10,421,120 | 1.90% |